These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31452381)

  • 61. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
    Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
    JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
    Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G
    Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.
    Lanini S; Scognamiglio P; Mecozzi A; Lombardozzi L; Vullo V; Angelico M; Gasbarrini A; Taliani G; Attili AF; Perno CF; De Santis A; Puro V; Cerqua F; D'Offizi G; Pellicelli A; Armignacco O; Mennini FS; Siciliano M; Girardi E; Panella V; Ippolito G;
    BMC Infect Dis; 2018 May; 18(1):223. PubMed ID: 29769038
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
    Fabbiani M; Lombardi A; Colaneri M; Del Poggio P; Perini P; D'Ambrosio R; Degasperi E; Dibenedetto C; Giorgini A; Pasulo L; Maggiolo F; Castelli F; Brambilla P; Spinelli O; Re T; Lleo A; Rumi M; Uberti-Foppa C; Soria A; Aghemo A; Lampertico P; Baiguera C; Schiavini M; Fagiuoli S; Bruno R;
    J Viral Hepat; 2021 Mar; 28(3):558-568. PubMed ID: 33306247
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study.
    Nsanzimana S; Penkunas MJ; Liu CY; Sebuhoro D; Ngwije A; Remera E; Umutesi J; Ntirenganya C; Mugeni SD; Serumondo J
    Clin Infect Dis; 2021 Nov; 73(9):e3300-e3307. PubMed ID: 32505127
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
    Gambato M; Canini L; Lens S; Graw F; Perpiñan E; Londoño MC; Uprichard SL; Mariño Z; Reverter E; Bartres C; González P; Pla A; Costa J; Burra P; Cotler SJ; Forns X; Dahari H
    Liver Int; 2019 May; 39(5):826-834. PubMed ID: 30499631
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
    Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Alem SA; Eletreby R; Abdellatif Z; Ramadan A; Nagy A; AbdAllah M; Elsharkawy A; Fouad R; Esmat G; Tantawi O
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e746-e752. PubMed ID: 34231522
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study.
    Pugliese N; Giorgini A; Maggi D; Capogreco A; Dibenedetto C; Lubrano Lobianco F; Dal Buono A; Monico S; Meli R; Battezzati PM; Lleo A; De Santis A; Zuin M; Aghemo A
    Expert Opin Drug Saf; 2021 Jul; 20(7):839-843. PubMed ID: 33881366
    [No Abstract]   [Full Text] [Related]  

  • 71. Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.
    Davidov Y; Kleinbaum Y; Inbar Y; Cohen-Ezra O; Veitsman E; Weiss P; Likhter M; Berdichevski T; Katsherginsky S; Hassid A; Tsaraf K; Silverberg D; Ben Ari Z
    Isr Med Assoc J; 2021 Dec; 23(12):794-800. PubMed ID: 34954919
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience.
    Tsai MC; Lin CY; Hung CH; Lu SN; Tung SY; Chien RN; Lin CL; Wang JH; Chien-Hung C; Chang KC; Hu TH; Sheen IS
    J Viral Hepat; 2019 Dec; 26(12):1404-1412. PubMed ID: 31433885
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital.
    Hawsawi NM; Saber T; Salama HM; Fouad WS; Hagag HM; Alhuthali HM; Eed EM; Saber T; Ismail KA; Al Qurashi HH; Altowairqi S; Samaha M; El-Hossary D
    Trop Med Infect Dis; 2023 Jan; 8(2):. PubMed ID: 36828508
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance.
    Russo FP; Zanetto A; Gambato M; Bortoluzzi I; Al Zoairy R; Franceschet E; De Marchi F; Marzi L; Lynch EN; Floreani A; Farinati F; Schaefer B; Burra P; Zoller H; Mega A
    J Viral Hepat; 2020 Feb; 27(2):188-194. PubMed ID: 31596996
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
    Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
    World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study.
    Kaur H; Dhiman RK; Kulkarni AV; Premkumar M; Singh V; Duseja AK; Grover S; Grover GS; Roy A; Verma N; De A; Taneja S; Mehtani R; Mishra S; Kaur H
    J Viral Hepat; 2022 May; 29(5):395-406. PubMed ID: 35266624
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals.
    Seko Y; Moriguchi M; Takahashi A; Okishio S; Kataoka S; Okuda K; Mizuno N; Takemura M; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
    Intern Med; 2020; 59(15):1811-1817. PubMed ID: 32741890
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Outcomes of Direct-Acting Antiviral Treatment of Psychiatric Patients with Comorbid Hepatitis C Virus Infection.
    Gayam V; Jegede O; Tiongson B; Mandal AK; Sidhu J; Garlapati P
    Dig Dis; 2020; 38(3):232-239. PubMed ID: 31494648
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era.
    Devresse A; Delire B; Lazarus JV; Kabamba B; De Meyer M; Mourad M; Buemi A; Darius T; Cambier JF; Goffin E; Jadoul M; Kanaan N
    Transplant Proc; 2020 Apr; 52(3):815-822. PubMed ID: 32143864
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    Atsukawa M; Tsubota A; Kondo C; Toyoda H; Takaguchi K; Nakamuta M; Watanabe T; Morishita A; Tani J; Okubo H; Hiraoka A; Nozaki A; Chuma M; Kawata K; Uojima H; Ogawa C; Asano T; Mikami S; Kato K; Matsuura K; Ikegami T; Ishikawa T; Tsuji K; Tada T; Tsutsui A; Senoh T; Kitamura M; Okubo T; Arai T; Kohjima M; Morita K; Akahane T; Nishikawa H; Iwasa M; Tanaka Y; Iwakiri K
    J Gastroenterol; 2024 Aug; 59(8):709-718. PubMed ID: 38727822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.